Skip to main content
. 2017 Jun 29;8(57):97613–97622. doi: 10.18632/oncotarget.18811

Figure 1. CT scans depiction of lipiodol deposition in TACE alone and TACE + sorafenib group.

Figure 1

(A) Lipiodol deposition in the right lobe of liver in TACE alone group. (B) Increased lipiodol deposition in the right lobe of liver in TACE + sorafenib group.